These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35489011)

  • 1. Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases-cross-sectional study from a reference centre in Spain.
    Udaondo C; Millán-Longo C; Permuy C; Valladares L; Falces-Romero I; Muñoz-Gómez C; Morales-Higuera M; Alcobendas R; Remesal A; Murias S; Calvo C
    Clin Rheumatol; 2022 Jun; 41(6):1779-1784. PubMed ID: 35489011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease.
    Walters HM; Mian Z; Thomas L; Cerise J; Eberhard BA; Pagano E; Gottlieb BS; Steigerwald K; Hui-Yuen JS
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI112-SI119. PubMed ID: 34599820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.
    Haslak F; Ozbey D; Yildiz M; Adrovic A; Sahin S; Koker O; Aliyeva A; Guliyeva V; Yalcin G; Inanli G; Kocazeybek BS; Kasapcopur O; Barut K
    Clin Rheumatol; 2022 May; 41(5):1523-1533. PubMed ID: 35044502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.
    Sengler C; Eulert S; Minden K; Niewerth M; Horneff G; Kuemmerle-Deschner J; Siemer C; Berendes R; Girschick H; Hühn R; Borte M; Hospach A; Emminger W; Armann J; Klein A; Kallinich T
    RMD Open; 2021 Jul; 7(2):. PubMed ID: 34312307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases.
    Clemente D; Udaondo C; de Inocencio J; Nieto JC; Del Río PG; Fernández AG; Palomo JA; Bachiller-Corral J; Lopez Robledillo JC; Millán Longo C; Leon L; Abasolo L; Boteanu A
    Pediatr Rheumatol Online J; 2021 Nov; 19(1):162. PubMed ID: 34838054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
    Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
    Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
    Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
    Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases.
    Gros C; Mariaggi AA; Meritet JF; André E; Boisson M; Combier A; Descamps E; Frantz C; Wanono S; Morel J; Avouac J; Rozenberg F; Miceli-Richard C; Fogel O
    Joint Bone Spine; 2022 May; 89(3):105312. PubMed ID: 34883243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
    Varona JF; Madurga R; Peñalver F; Abarca E; Almirall C; Cruz M; Ramos E; Castellano Vázquez JM
    Int J Epidemiol; 2021 May; 50(2):400-409. PubMed ID: 33434269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry.
    Isnardi CA; Roberts K; Saurit V; Petkovic I; Báez RM; Quintana R; Tissera Y; Ornella S; D Angelo Exeni ME; Pisoni CN; Castro Coello VV; Berbotto G; Haye Salinas MJ; Velozo E; Reyes Torres ÁA; Tanten R; Zelaya MD; Gobbi C; Alonso CG; de Los Ángeles Severina M; Vivero F; Paula A; Cogo AK; Alle G; Pera M; Nieto RE; Cosatti M; Asnal C; Pereira D; Albiero JA; Savio VG; Maldonado FN; Gamba MJ; Germán NF; Baños A; Gallino Yanzi J; Gálvez Elkin MS; Morbiducci JS; Martire MV; Maldonado Ficco H; Schmid MM; Villafañe Torres JA; de Los Ángeles Correa M; Medina MA; Cusa MA; Scafati J; Agüero SE; Lloves Schenone NM; Soriano ER; Graf C; Pons-Estel BA; Gomez G; Landi M; De la Vega MC; Pons-Estel GJ;
    Clin Rheumatol; 2023 Feb; 42(2):563-578. PubMed ID: 36201124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroconversion in asymptomatic COVID-19 pediatric patients with rheumatic diseases of one tertiary referral hospital.
    Simon JR; Pereira MFB; Marques HH; Elias AM; Sakita NK; Ferreira JCOA; Precioso AR; Grisi SJFE; Ferrer APS; Bain V; Silva CA; Campos LMA
    Clinics (Sao Paulo); 2022; 77():100110. PubMed ID: 36179528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases.
    Kearsley-Fleet L; Chang ML; Lawson-Tovey S; Costello R; Fingerhutová Š; Švestková N; Belot A; Aeschlimann FA; Melki I; Koné-Paut I; Eulert S; Kallinich T; Berkun Y; Uziel Y; Raffeiner B; Oliveira Ramos F; Clemente D; Dackhammar C; Wulffraat NM; Waite H; Strangfeld A; Mateus EF; Machado PM; ; ; Natter M; Hyrich KL
    Ann Rheum Dis; 2022 Jul; 81(7):998-1005. PubMed ID: 35338032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases.
    Eviatar T; Furer V; Polachek A; Levartovsky D; Elalouf O; Zisapel M; Halperin T; Turner D; Paran D; Pel S; Nevo S; Elkayam O
    Clin Exp Rheumatol; 2022 Jul; 40(7):1299-1305. PubMed ID: 34494961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.
    Peremiquel-Trillas P; Saura-Lázaro A; Benavente-Moreno Y; Casabonne D; Loureiro E; Cabrera S; Duran A; Garrote L; Brao I; Trelis J; Galán M; Soler F; Julià J; Cortasa D; Domínguez MÁ; Albasanz-Puig A; Gudiol C; Ramírez-Tarruella D; Muniesa J; Rivas JP; Muñoz-Montplet C; Sedano A; Plans À; Calvo-Cerrada B; Calle C; Clopés A; Carnicer-Pont D; Alemany L; Fernández E
    BMJ Open; 2022 Apr; 12(4):e056637. PubMed ID: 35450905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the outcomes of SARS-CoV-2 infection in children and young people followed at Portuguese pediatric rheumatology clinics.
    Melo AT; Bernardo M; Pinheiro F; Rodrigues M; Torres R; Mourão AF; Carvalho S; Nascimento J; Sousa S; Santos MJ; Soares C; Cabral M; Marques RC; Reis PC; Ramos FO
    ARP Rheumatol; 2022 Oct; 1(ARP Rheumatology, nº3 2022):205-209. PubMed ID: 36056926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 seroprevalence in patients with autoimmune rheumatic diseases versus family controls: a multi-city cross-sectional survey.
    Misra R; Bhattacharya D; Ahmed S; Amin S; Shobha V; Ghosh A; Pandya SC; Parai D; Padhan P; Priyadarshini S; Mohapatra I; Patro ARK; Mohanty AP; Pati S
    Rheumatol Int; 2024 Jan; 44(1):81-87. PubMed ID: 37906254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.